CN100484573C - Method for preparing floating-biological adhesion synergistic microparticle - Google Patents
Method for preparing floating-biological adhesion synergistic microparticle Download PDFInfo
- Publication number
- CN100484573C CN100484573C CNB2005100468188A CN200510046818A CN100484573C CN 100484573 C CN100484573 C CN 100484573C CN B2005100468188 A CNB2005100468188 A CN B2005100468188A CN 200510046818 A CN200510046818 A CN 200510046818A CN 100484573 C CN100484573 C CN 100484573C
- Authority
- CN
- China
- Prior art keywords
- sodium alginate
- chitosan
- floating
- microparticles
- ethyl cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种漂浮-生物粘附协同型微粒的制备方法,先以水中干燥体系制备乙基纤维素漂浮微球,然后在乳化体系中用海藻酸钠包衣,最后把海藻酸钠-乙基纤维素微粒分散在壳聚糖溶液中发生离子凝胶化,形成壳聚糖膜,制得漂浮-生物粘附微粒。本发明制备微粒的原材料是广泛用于药学研究和应用领域的、具有良好的生物相容性的生物材料乙基纤维素、海藻酸钠、壳聚糖。这种漂浮-生物粘附协同型微粒可用于运载胃内发挥作用的水微溶或水不溶小分子药物,也可用于运载胃部吸收的许多酸性药物以及在十二指肠以上消化道部位吸收的药物。该制剂能显著延长药物在胃内的滞留时间,提高药物的生物利用度。The invention relates to a preparation method of floating-bioadhesion synergistic microparticles. Firstly, ethyl cellulose floating microspheres are prepared in a water drying system, then coated with sodium alginate in an emulsification system, and finally sodium alginate-ethyl cellulose The cellulose-based microparticles are dispersed in the chitosan solution to undergo ion gelation to form a chitosan film to obtain floating-bioadhesive microparticles. The raw materials for preparing microparticles in the invention are ethyl cellulose, sodium alginate and chitosan, which are widely used in pharmaceutical research and application fields and have good biocompatibility. This floating-bioadhesive synergistic particle can be used to carry small water-soluble or water-insoluble small molecule drugs that function in the stomach, and can also be used to carry many acidic drugs absorbed in the stomach and absorbed in the digestive tract above the duodenum Drug. The preparation can significantly prolong the residence time of the drug in the stomach and improve the bioavailability of the drug.
Description
技术领域 technical field
本发明涉及一种制备胃内漂浮-生物粘附协同型微粒制剂的方法,其采用水中干燥-乳化/内部凝胶化耦合技术,制备微粒的原材料是广泛用于药学研究和应用领域的、具有良好的生物相容性的生物材料乙基纤维素、海藻酸钠、壳聚糖。这种漂浮-生物粘附协同型微粒可用于运载胃内发挥作用的水微溶或水不溶小分子药物,也可用于运载胃部吸收的许多酸性药物以及在十二指肠以上消化道部位吸收的药物。该制剂能显著延长药物在胃内的滞留时间,提高药物的生物利用度。The invention relates to a method for preparing intragastric floating-bioadhesion synergistic microparticle preparations, which adopts the drying-emulsification/internal gelation coupling technology in water, and the raw materials for preparing microparticles are widely used in pharmaceutical research and application fields, and have the advantages of Good biocompatibility biomaterials ethyl cellulose, sodium alginate, chitosan. This floating-bioadhesive synergistic particle can be used to carry small water-soluble or water-insoluble small molecule drugs that function in the stomach, and can also be used to carry many acidic drugs absorbed in the stomach and absorbed in the digestive tract above the duodenum Drug. The preparation can significantly prolong the residence time of the drug in the stomach and improve the bioavailability of the drug.
背景技术 Background technique
传统的口服缓(控)释给药系统,给药后释放其所载的药物到胃肠道中,并随着胃排空和肠道的蠕动,在体内经历着变迁过程。但是,如果药物的吸收仅在胃肠道的特定部位进行或主要在某一区段进行(例如在胃内或小肠的上段),那么这种控释药物输送系统,在胃内及小肠内滞留时间较短(一般在1—2h),因而吸收时间相对较短,生物利用度低,难以实现其预期的治疗目的。The traditional oral sustained (controlled) release drug delivery system releases the loaded drug into the gastrointestinal tract after administration, and undergoes a change process in the body with gastric emptying and intestinal peristalsis. However, if the drug is absorbed only in a specific part of the gastrointestinal tract or mainly in a certain section (such as in the stomach or the upper part of the small intestine), then this controlled-release drug delivery system will remain in the stomach and small intestine. The time is short (generally 1-2h), so the absorption time is relatively short, the bioavailability is low, and it is difficult to achieve its intended therapeutic purpose.
胃内滞留制剂是一类能延长药物在胃内的滞留时间(一般大于4h),从而延长药物在整个胃肠道的转运,促进药物的吸收,提高药物的生物利用度的新型制剂[文献1.Jaspreet K,Kaustubh T,Sanjay G Bioadhesive microspheres as a controlled drugdelivery system.Int.J.Pharm,2003,255:13-32];该制剂能降低给药频率,方便给药,为解决药物生物利用度低这一问题提供了一个新途径。Gastric retention preparations are a class of new preparations that can prolong the residence time of drugs in the stomach (generally greater than 4 h), thereby prolonging the transport of drugs throughout the gastrointestinal tract, promoting drug absorption, and improving drug bioavailability [Document 1 .Jaspreet K, Kaustubh T, Sanjay G Bioadhesive microspheres as a controlled drugdelivery system.Int.J.Pharm, 2003,255:13-32]; This problem provides a new approach.
胃内滞留制剂主要分为以下几种:漂浮型、生物粘附型及漂浮-生物粘附协同型。剂型主要有片剂、胶囊、微球等。其中漂浮-生物粘附协同型微球(微粒)以多个微小单位存在,比表面积增大,生物粘附面积增大,并且呈漂浮状态的小单位按概率分布,增加了漂浮的机会,显著延长药物在胃肠道的转运时间。Gastric retention preparations are mainly divided into the following types: floating type, bioadhesive type and floating-bioadhesive synergistic type. Dosage forms mainly include tablets, capsules, microspheres, etc. Among them, the floating-bioadhesion synergistic microspheres (particles) exist in multiple tiny units, the specific surface area increases, the bioadhesion area increases, and the small units in the floating state are distributed according to the probability, which increases the chance of floating, significantly Prolong the transit time of the drug in the gastrointestinal tract.
目前制备漂浮-生物粘附协同型微球(微粒)的方法和使用的材料[文献2.黄静琳,陆锦芳.甲硝唑生物粘附微球的体外释药及其粘附性.药学学报.2002,37(3):226-228;文献3.Akiyama Y,Nagahara N,KashiharaT,et al.In vitro and in vivoevaluation of mucoadhesive microspheres prepared for the gastrointestinal tract usingpolyglycerol esters of fatty acids and a poly(acrylic acid)derivative.Pharm Res,1995,12(3):397-405;文献4.Umamaheswari RB,Jain S,Tripathi PK,Agrawal GP,Jain NK.Floating-bioadhesive microspheres containing acetohydroxamic acid for clearance ofHelicobacter pylori.Drug Delivery,2002,9:223-231;文献5.Lehr CM,Bbounstra JA,Tukker J,et al.Intestinal transit of bioadhesive microspheres in an situ loop in the rat-acomparative study with copolymers and blends and based on poly(acrylic acid).JControl Release,1990,13:51-62;文献6.Yasunori M,Kanako O,Shigeru Y,et al.Invitro and in vivo evaluation of mucoadhesive microspheres consisting of dextranderivatives and cellulose acetate butyrate.Int.J.Pharm,2003,258:21-29;文献7.JianW,Yasuhiko T,Dianzhou B,et al.Evaluation of gastric mucoadhesive properties ofaminated gelatin microspheres.J Control Release,2001,73:223-231]有:1、分散型微球(微粒),以卡波姆作为生物粘附材料,将其分散在乙基纤维素有机溶剂中,采用油中干燥法制备乙基纤维素生物粘附微球。因卡波姆在水中溶胀,不能采用水中干燥法制备微球,故所需时间较长,温度较高;同时卡波姆含量大,虽能提高生物粘附性能,但同时降低制剂的漂浮能力。2、包衣型微球(微粒),将制备好的微球,外用生物粘附材料对其表面进行包衣或修饰。常用的包衣材料有卡波姆、羟丙基纤维素、丙烯酸树脂Eudragit S等,这些材料在微球表面形成凝胶层,但是在胃肠道转运过程中,遇胃液有时会过度吸水溶胀,易与微球脱落,从而使药物过早释放,并且粘附性能下降。引入戊二醛等交联剂,虽然能在一定程度上控制凝胶层的过度吸水溶胀现象,但是交联剂对机体产生一定的毒性,有时与药物发生反应,降低了药效。The current method and materials used to prepare floating-bioadhesive synergistic microspheres (microparticles) [
发明内容 Contents of the invention
本发明提供一种制备胃内漂浮-生物粘附协同型微粒制剂的方法。其原理是:先以乙基纤维素为基质制备疏水性漂浮微球,然后包衣海藻酸钠、壳聚糖生物粘附材料,通过提高制剂在胃内的漂浮性能及生物粘附性能,显著延长药物在胃内的滞留时间,提高药物的生物利用度。The invention provides a method for preparing gastric floating-bioadhesion synergistic microparticle preparation. The principle is: first prepare hydrophobic floating microspheres with ethyl cellulose as the matrix, and then coat sodium alginate and chitosan bioadhesive materials. By improving the floating performance and bioadhesive performance of the preparation in the stomach, it significantly Prolong the residence time of the drug in the stomach and improve the bioavailability of the drug.
本发明的技术方案为:Technical scheme of the present invention is:
一种胃内漂浮-生物粘附协同型微粒的制备方法,具有如下步骤:1)先以水中干燥体系制备乙基纤维素漂浮微球;2)然后在乳化体系中用海藻酸钠包衣形成海藻酸钙-乙基纤维素微粒;3)最后把海藻酸钠-乙基纤维素微粒分散在壳聚糖溶液中发生离子凝胶化形成壳聚糖膜,制得漂浮-生物粘附微粒。A method for preparing floating-bioadhesion synergistic microparticles in the stomach, comprising the following steps: 1) preparing ethylcellulose floating microspheres in a water drying system; 2) coating them with sodium alginate in an emulsified system to form Calcium alginate-ethylcellulose microparticles; 3) Finally, sodium alginate-ethylcellulose microparticles are dispersed in a chitosan solution to undergo ion gelation to form a chitosan film to obtain floating-bioadhesive microparticles.
具体步骤如下:Specific steps are as follows:
(1)针对油中干燥法采用的分散体系是液体石蜡为分散介质和Span 80为表面活性剂,得到的微球的清洗过程繁琐,因此,本发明采用新的分散体系即水为分散介质和聚乙烯醇(PVA)为表面活性剂,将药物和乙基纤维素溶于二氯甲烷等溶剂中,以水中干燥法制备了球形度较好的乙基纤维素微球。(1) liquid paraffin is that dispersion medium and Span 80 are tensio-active agent at the dispersion system that drying method adopts in the oil, and the cleaning process of the microsphere that obtains is loaded down with trivial details, therefore, the present invention adopts new dispersion system that water is dispersion medium and Polyvinyl alcohol (PVA) was used as a surfactant, and the drug and ethyl cellulose were dissolved in dichloromethane and other solvents, and ethyl cellulose microspheres with good sphericity were prepared by drying in water.
具体为:以二氯甲烷、氯仿、四氯化碳或正己烷等作为溶剂的重量浓度为1~15%(w/v)的乙基纤维素溶液作为分散相(O),重量浓度0.5~10%(w/v)聚乙烯醇(PVA)或0.01%-0.2%(w/v)十二烷基磺酸钠的水溶液作为连续相(W),将分散相分散到连续相中,O/W体积比为1:40~1:10,温度控制在20~40℃,在600~1200rpm的转速下搅拌2~5h,制备出不同粒径(50~200μm)的乙基纤维素微球。Specifically: the ethyl cellulose solution with dichloromethane, chloroform, carbon tetrachloride or n-hexane, etc. as a solvent with a weight concentration of 1 to 15% (w/v) as the dispersed phase (O), with a weight concentration of 0.5 to 10% (w/v) polyvinyl alcohol (PVA) or 0.01%-0.2% (w/v) aqueous solution of sodium dodecylsulfonate as the continuous phase (W), disperse the dispersed phase into the continuous phase, O The /W volume ratio is 1:40~1:10, the temperature is controlled at 20~40°C, and stirred at a speed of 600~1200rpm for 2~5h to prepare ethyl cellulose microspheres with different particle sizes (50~200μm). .
(2)再以海藻酸钠作为包衣材料,将干燥的乙基纤维素微球分散在海藻酸钠溶液中,采用乳化/内部凝胶化法制备海藻酸钙-乙基纤维素微粒。乳化/内部凝胶化方法的原理是将海藻酸钠溶液和难溶性钙盐:碳酸钙、乳酸钙、草酸钙颗粒分散到油相的液体石蜡中,在合适的表面活性剂Span 80作用下形成油包水(W/O)型乳状液。然后通过降低体系的pH解离出难溶性钙盐中的钙离子而引发海藻酸钠的凝胶化反应,生成海藻酸钙凝胶珠。(2) Using sodium alginate as a coating material, disperse the dried ethylcellulose microspheres in the sodium alginate solution, and prepare calcium alginate-ethylcellulose microparticles by emulsification/internal gelation method. The principle of the emulsification/internal gelation method is to disperse sodium alginate solution and insoluble calcium salts: calcium carbonate, calcium lactate, calcium oxalate particles into liquid paraffin in the oil phase, and form under the action of a
具体为:将制备好的乙基纤维素微球及0.05~0.3mol/L难溶钙盐(可为碳酸钙、乳酸钙功草酸钙)均匀分散到重量浓度0.5~3%(w/v)海藻酸钠溶液中,然后将混合液分散到含有重量浓度0.5~2.5%(w/v)司盘80(Span80)和0.5~2.5%(w/v)吐温20(Tween20)的液体石蜡中,水油相体积比在1:4~1:10,在600~1200rpm的转速下搅拌15~40min;以冰醋酸为凝胶引发剂调节体系的pH=3.0~6.5(通常加10~50%(v/v)冰醋酸0.2-10ml即可),继续搅拌5~20min,即可得到AE微粒(海藻酸钙-乙基纤维素微粒);乙基纤维素微球与海藻酸钠溶液的质量比为1:1-4。Specifically: uniformly disperse the prepared ethylcellulose microspheres and 0.05-0.3mol/L insoluble calcium salt (can be calcium carbonate, calcium lactate, calcium oxalate) to a weight concentration of 0.5-3% (w/v) Sodium alginate solution, and then disperse the mixture into liquid paraffin containing 0.5-2.5% (w/v) Span 80 (Span80) and 0.5-2.5% (w/v) Tween 20 (Tween20) by weight , the volume ratio of the water-oil phase is 1:4-1:10, stirring at a speed of 600-1200rpm for 15-40min; using glacial acetic acid as the gel initiator to adjust the pH of the system to 3.0-6.5 (usually adding 10-50% (v/v) 0.2-10ml of glacial acetic acid), and continue to stir for 5-20 minutes to obtain AE particles (calcium alginate-ethylcellulose particles); the mass of ethylcellulose microspheres and sodium alginate solution The ratio is 1:1-4.
(3)为增强海藻酸钙-乙基纤维素微粒的生物粘附性能,采用离子交联法制备壳聚糖-海藻酸钙-乙基纤维素微粒:将制备好的AE微粒(海藻酸钙-乙基纤维素微粒)分散在壳聚糖溶液中,振摇反应5~30min,即得壳聚糖-海藻酸钙-乙基纤维素微粒。使用的壳聚糖pH在3.0~6.5之间,重量浓度在0.25~5%之间,温度控制在20~40℃。(3) In order to enhance the bioadhesion performance of calcium alginate-ethylcellulose microparticles, chitosan-calcium alginate-ethylcellulose microparticles were prepared by ion cross-linking: the prepared AE microparticles (calcium alginate - ethylcellulose microparticles) dispersed in chitosan solution, shaken for 5-30 minutes to react to obtain chitosan-calcium alginate-ethylcellulose microparticles. The pH of the chitosan used is between 3.0-6.5, the weight concentration is between 0.25-5%, and the temperature is controlled at 20-40°C.
本发明的优点为:The advantages of the present invention are:
1.本发明制备过程及操作简单,温度低,所需时间短,整体时间约在3-10h,制备的微粒具有漂浮及生物粘附的特点。1. The preparation process and operation of the present invention are simple, the temperature is low, and the required time is short. The overall time is about 3-10 hours, and the prepared particles have the characteristics of floating and biological adhesion.
2.本发明采用海藻酸钠与钙离子进行离子交联的方法制备微粒,反应条件温和,避免了引入戊二醛等有毒性的交联剂,因此减少毒性,且生物相容性较好,避免使用化学交联剂带来的不良反应。2. The present invention uses sodium alginate and calcium ions to carry out ionic cross-linking to prepare microparticles, the reaction conditions are mild, and the introduction of toxic cross-linking agents such as glutaraldehyde is avoided, so the toxicity is reduced and the biocompatibility is better. Avoid adverse reactions caused by the use of chemical cross-linking agents.
3.本发明壳聚糖-海藻酸钙-乙基纤维素微粒在pH5.0的醋酸缓冲液中具有良好的漂浮性能,70%的微粒的飘浮时间大于4h。3. The chitosan-calcium alginate-ethylcellulose microparticles of the present invention have good floating performance in the acetate buffer solution of pH 5.0, and the floating time of 70% of the microparticles is greater than 4h.
4.本发明采用壳聚糖与海藻酸钠进行离子交联,壳聚糖包衣海藻酸钙-乙基纤维素微粒,增强了体系的生物粘附性能,具有较好的体外生物粘附性能,以22ml/min的速度冲洗5min,90%以上的微粒粘附在胃粘膜表面。4. The present invention uses chitosan and sodium alginate for ion cross-linking, and chitosan coats calcium alginate-ethyl cellulose particles, which enhances the bioadhesion performance of the system and has better in vitro bioadhesion performance , washed at a speed of 22ml/min for 5min, and more than 90% of the particles adhered to the surface of the gastric mucosa.
附图说明 Description of drawings
图1为本发明海藻酸钙-乙基纤维素微粒的显微镜照片;其中A为海藻酸钙-乙基纤维素微粒×4,B为海藻酸钙-乙基纤维素微粒×10;Fig. 1 is the micrograph of calcium alginate-ethyl cellulose particle of the present invention; Wherein A is calcium alginate-ethyl cellulose particle × 4, B is calcium alginate-ethyl cellulose particle × 10;
图2为本发明壳聚糖-海藻酸钙-乙基纤维素微粒的显微镜照片×10;Fig. 2 is the microscope photo * 10 of chitosan-calcium alginate-ethylcellulose particle of the present invention;
图3为本发明壳聚糖-海藻酸钙-乙基纤维素微粒在pH5.0的醋酸缓冲液中的飘浮时间曲线。Fig. 3 is the floating time curve of chitosan-calcium alginate-ethylcellulose microparticles in pH 5.0 acetate buffer of the present invention.
具体实施方式 Detailed ways
如图1、图2所示,本技术制备的漂浮-生物粘附微粒粒径在150~1000μm,根据不同需要制备出包裹1~6个或更多个乙基纤维素微球的壳聚糖-海藻酸钙-乙基纤维素微粒。As shown in Figure 1 and Figure 2, the particle size of the floating-bioadhesive particles prepared by this technology is 150-1000 μm, and chitosan wrapped with 1-6 or more ethylcellulose microspheres can be prepared according to different needs - Calcium Alginate - Ethyl Cellulose Microparticles.
具体实施办法如下:The specific implementation method is as follows:
实施例1:以二氯甲烷为溶剂,浓度4%(w/v)的乙基纤维素溶液作为分散相(O),以浓度0.5%(w/v)聚乙烯醇(PVA)和浓度0.01%(w/v)十二烷基磺酸钠水溶液作为连续相(W),O/W比为1:40,温度控制在20℃,搅拌速度1200rpm,搅拌时间5h,制备出粒径为50~100μm的乙基纤维素微球。将制备好的乙基纤维素微球及0.05mol/L难溶钙盐均匀分散到0.5%(w/v)海藻酸钠溶液中,然后将混合液分散到含有0.5%(w/v)司盘80(Span80)和0.5%(w/v)吐温20(Tween20)的液体石蜡中,水油相体积比在1:4之间,加10%(v/v)冰醋酸0.2ml,继续搅拌20min,温度控制在20℃,即可得到海藻酸钠-乙基纤维素微粒。将制备好的海藻酸钠-乙基纤维素微粒分散在壳聚糖溶液中,振摇反应5min,即得壳聚糖-海藻酸钠-乙基纤维素微粒,使用的壳聚糖pH在3.0,浓度在0.25%,温度控制在20℃。Embodiment 1: take dichloromethane as solvent, the ethyl cellulose solution of
实施例2:以氯仿为溶剂,浓度15%(w/v)的乙基纤维素溶液作为分散相(O),以浓度10%(w/v)聚乙烯醇(PVA)和浓度0.2%(w/v)十二烷基磺酸钠水溶液作为连续相(W),O/W比为1:10,温度控制在40℃,搅拌速度600rpm,搅拌时间2h,制备出粒径为100~200μm的乙基纤维素微球。将制备好的乙基纤维素微球及0.3mol/L难溶钙盐均匀分散到3%(w/v)海藻酸钠溶液中,然后将混合液分散到含有2.5%(w/v)司盘80(Span80)和2.5%(w/v)吐温20(Tween20)的液体石蜡中,水油相体积比在1:10之间,加50%(v/v)冰醋酸10ml,继续搅拌5min,温度控制在20℃,即可得到海藻酸钠-乙基纤维素微粒。将制备好的海藻酸钠-乙基纤维素微粒分散在壳聚糖溶液中,振摇反应30min,即得壳聚糖-海藻酸钠-乙基纤维素微粒,使用的壳聚糖pH在6.5,浓度在5%,温度控制在20℃。Embodiment 2: take chloroform as solvent, the ethyl cellulose solution of concentration 15% (w/v) is as dispersed phase (O), with concentration 10% (w/v) polyvinyl alcohol (PVA) and concentration 0.2% ( w/v) Sodium dodecylsulfonate aqueous solution is used as the continuous phase (W), the O/W ratio is 1:10, the temperature is controlled at 40°C, the stirring speed is 600rpm, the stirring time is 2h, and the particle size is 100-200μm ethylcellulose microspheres. Evenly disperse the prepared ethylcellulose microspheres and 0.3mol/L insoluble calcium salt into a 3% (w/v) sodium alginate solution, and then disperse the mixed solution into a solution containing 2.5% (w/v) sodium alginate In the liquid paraffin of Pan 80 (Span80) and 2.5% (w/v) Tween 20 (Tween20), the volume ratio of water to oil phase is between 1:10, add 10ml of 50% (v/v) glacial acetic acid, and continue stirring 5min, the temperature is controlled at 20°C, and sodium alginate-ethylcellulose microparticles can be obtained. Disperse the prepared sodium alginate-ethylcellulose microparticles in the chitosan solution and shake for 30 minutes to obtain chitosan-sodium alginate-ethylcellulose microparticles. The pH of the chitosan used is 6.5 , the concentration is 5%, and the temperature is controlled at 20°C.
实施例3:以正己烷为溶剂,浓度1%(w/v)的乙基纤维素溶液作为分散相(O),以浓度2%(w/v)聚乙烯醇(PVA)和浓度0.1%(w/v)十二烷基磺酸钠水溶液作为连续相(W),O/W比为1:6,温度控制在30℃,搅拌速度900rpm,搅拌时间4h,制备出粒径为100~150μm的乙基纤维素微球。将制备好的乙基纤维素微球及0.2mol/L难溶钙盐均匀分散到1.5%(w/v)海藻酸钠溶液中,然后将混合液分散到含有1%(w/v)司盘80(Span80)和1%(w/v)吐温20(Tween20)的液体石蜡中,水油相体积比在1:6之间,加30%(v/v)冰醋酸5ml,继续搅拌15min,温度控制在30℃,即可得到海藻酸钠-乙基纤维素微粒。将制备好的海藻酸钠-乙基纤维素微粒分散在壳聚糖溶液中,振摇反应15min,即得壳聚糖-海藻酸钠-乙基纤维素微粒,使用的壳聚糖pH在5.0,浓度在2.5%,温度控制在30℃。Embodiment 3: take normal hexane as solvent, the ethyl cellulose solution of concentration 1% (w/v) is as dispersed phase (O), with
本发明实施效果:Implementation effect of the present invention:
1、体外模拟壳聚糖-海藻酸钙-乙基纤维素微粒在pH5.0的醋酸缓冲液中的飘浮情况,基本反映壳聚糖-海藻酸钙-乙基纤维素微粒在胃内的飘浮,漂浮时间越长,药物在体内滞留时间越长,越利于药物的吸收。如图3中曲线所示。1. In vitro simulation of the floating situation of chitosan-calcium alginate-ethylcellulose particles in the acetate buffer solution of pH 5.0, which basically reflects the floating of chitosan-calcium alginate-ethylcellulose particles in the stomach , the longer the floating time, the longer the drug stays in the body, which is more conducive to the absorption of the drug. As shown in the curve in Figure 3.
2、体外考察壳聚糖-海藻酸钙-乙基纤维素微粒在胃粘膜组织的残留量,微粒在胃粘膜组织的残留量越多,药物在粘膜的浓度越高。如表1。2. To investigate the residual amount of chitosan-calcium alginate-ethylcellulose microparticles in gastric mucosal tissue in vitro, the more the residual amount of microparticles in gastric mucosal tissue, the higher the drug concentration in mucosal tissue. As in Table 1.
表1 不同微粒在离体大鼠胃粘膜上的滞留率Table 1 Retention rate of different microparticles on isolated rat gastric mucosa
实验条件为:将禁食供水饲养24h后的大鼠随机分为3组,处死后取胃,平铺于载物台上。分别取乙基纤维素微球、海藻酸钠-乙基纤维素微粒及壳聚糖-海藻酸钠-乙基纤维素微粒各100粒,均匀撒在胃粘膜表面,置于饱和氯化钠溶液的密闭容器中,保湿20min后取出,使载物台呈45°斜角放置。用pH5醋酸缓冲液以22ml·min-1冲洗5min,记录淋洗后分别保留在胃粘膜组织上的微粒个数,获取滞留百分率。The experimental conditions were as follows: the rats fed with fasting and water supply for 24 hours were randomly divided into 3 groups, their stomachs were taken after sacrifice, and spread flat on the stage. Take 100 grains of ethyl cellulose microspheres, sodium alginate-ethyl cellulose micro-particles and chitosan-sodium alginate-ethyl cellulose micro-particles, sprinkle them evenly on the surface of the gastric mucosa, and place them in saturated sodium chloride solution In an airtight container, take it out after moisturizing for 20 minutes, and place the stage at an oblique angle of 45°. Rinse with pH 5 acetate buffer at 22ml·min-1 for 5min, record the number of particles remaining on the gastric mucosal tissue after rinsing, and obtain the retention percentage.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100468188A CN100484573C (en) | 2005-07-06 | 2005-07-06 | Method for preparing floating-biological adhesion synergistic microparticle |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100468188A CN100484573C (en) | 2005-07-06 | 2005-07-06 | Method for preparing floating-biological adhesion synergistic microparticle |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1891208A CN1891208A (en) | 2007-01-10 |
CN100484573C true CN100484573C (en) | 2009-05-06 |
Family
ID=37596573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100468188A Expired - Fee Related CN100484573C (en) | 2005-07-06 | 2005-07-06 | Method for preparing floating-biological adhesion synergistic microparticle |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100484573C (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406595B (en) * | 2011-11-02 | 2013-05-29 | 沈阳药科大学 | A floating bioadhesive porous hydrogel and its preparation method |
CN105326811B (en) * | 2015-12-02 | 2018-05-08 | 沈阳药科大学 | A kind of anthocyanidin floating in stomach microballoon and preparation method thereof |
CN107418998B (en) * | 2016-09-14 | 2020-02-28 | 四川蓝光英诺生物科技股份有限公司 | Microparticle manipulation method, bioprinting method and biological construct |
CN114130165B (en) * | 2020-09-03 | 2023-03-24 | 中国科学院大连化学物理研究所 | Recyclable ionic gel dehumidifying bag |
-
2005
- 2005-07-06 CN CNB2005100468188A patent/CN100484573C/en not_active Expired - Fee Related
Non-Patent Citations (10)
Title |
---|
口服生物粘附性给药系统. 魏淑波.镇江医学院学报,第11卷第1期. 2001 |
口服生物粘附性给药系统. 魏淑波.镇江医学院学报,第11卷第1期. 2001 * |
海藻酸钠-壳聚糖微胶囊膜强度的研究. 刘群,薛伟明,于炜婷,刘袖洞,严若媛,李金云,马小军.高等学校化学学报,第23卷第7期. 2002 |
海藻酸钠-壳聚糖微胶囊膜强度的研究. 刘群,薛伟明,于炜婷,刘袖洞,严若媛,李金云,马小军.高等学校化学学报,第23卷第7期. 2002 * |
漂浮药物传递系统的新进展-中空微球. 袁悦,李三鸣,莫凤奎.沈阳药科大学学报,第22卷第3期. 2005 |
漂浮药物传递系统的新进展-中空微球. 袁悦,李三鸣,莫凤奎.沈阳药科大学学报,第22卷第3期. 2005 * |
胃滞留-漂浮型给药系统研究进展. 黄晓君,屠锡德.药学进展,第28卷第5期. 2004 |
胃滞留-漂浮型给药系统研究进展. 黄晓君,屠锡德.药学进展,第28卷第5期. 2004 * |
避蚊胺乙基纤维素微球的制备及其性质考察. 高静,管斐,高申.第二军医大学学报,第25卷第11期. 2004 |
避蚊胺乙基纤维素微球的制备及其性质考察. 高静,管斐,高申.第二军医大学学报,第25卷第11期. 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1891208A (en) | 2007-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102970984B (en) | The microgranule of opposing conversion and microplate | |
Hari et al. | Chitosan/calcium alginate microcapsules for intestinal delivery of nitrofurantoin | |
AU737818B2 (en) | Gastroretentive controlled release microspheres for improved drug delivery | |
Builders et al. | Preparation and evaluation of mucinated sodium alginate microparticles for oral delivery of insulin | |
Arica et al. | In vitro and in vivo studies of ibuprofen-loaded biodegradable alginate beads | |
CN1294509A (en) | Enteric coated pharmaceutical composition and preparation method thereof | |
CN101940554B (en) | Multi-core adhesive microspheres for loading water soluble low molecular medicament and preparation method thereof | |
NZ335815A (en) | Drug delivery compositions for mucosal surfaces including microparticles comprising chitosan and type A cationic gelatin and a therapeutic agent and use | |
US9833436B2 (en) | Method of preparing drug agglomerate | |
JP2011524890A (en) | Pharmaceutical dosage forms for site-specific delivery of more than one active pharmaceutical ingredient | |
CN1744889A (en) | Controlled release pharmaceutical compositions of tamsulosin | |
Das et al. | Evaluation of diltiazem hydrochloride-loaded mucoadhesive microspheres prepared by emulsification-internal gelation technique | |
CN100484573C (en) | Method for preparing floating-biological adhesion synergistic microparticle | |
RU2375047C2 (en) | Pharmaceutical medicinal form, resistant to gastric juice activity, which includes n-(2-(2-phthalimidoetoxy)acetyl)-l-alanyl-d-glutamic acid (lk 423) | |
Tran et al. | Mucoadhesive formulation designs for oral controlled drug release at the colon | |
Mehta et al. | Solvent evaporation technique: An innovative approach to increase gastric retention | |
Alzaher et al. | Gastroretentive formulations for improving oral bioavailability of drugs-focus on microspheres and their production | |
CN103315959B (en) | Orally taken colon-targeted preparation for treatment of inflammatory bowel diseases and preparation method thereof | |
CN1771913B (en) | Emulifying solvent diffusing process for preparing taste masked micro ball | |
CN104306340B (en) | Slow controlled release microparticle of a kind of Allopurinol and preparation method thereof | |
Sultana et al. | An approach for lacidipine loaded gastroretentive formulation prepared by different methods for gastroparesis in diabetic patients | |
CN1232386A (en) | Colonic delivery of weak acid drugs | |
CN104367555B (en) | Bioadhesion type hollow microsphere and preparation method thereof | |
CN1957936A (en) | Silybin tiny pellets and preparation method | |
Verma et al. | RecentAdvances in Microspheres Technology for Drug Delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090506 Termination date: 20160706 |